Literature DB >> 11844908

Effects of urinary trypsin inhibitor in patients at risk for premature labor with a bulging fetal membrane.

Yoshio Matsuda1, Naoki Yunohara.   

Abstract

OBJECTIVE: To investigate the effect of urinary trypsin inhibitor (UTI) in patients at risk for premature labor with bulging membrane.
METHODS: Patients who had developed a bulging membrane from 22 to 27 weeks and 6 days of gestation were studied. These cases were divided into two types based on the severity: those with a moderately developed bulging membrane like a 'dome' (dome type), and those with a membrane prolapsed into the vagina, resulting in an 'hourglass' shape (hourglass type). We compared the outcomes of treatment with or without UTI (UTI group versus non-UTI group) in each type. Gestational age at delivery, birth weight, prolongation time from admission to delivery, and neonatal mortality rate were examined in each group.
RESULTS: A total of 43 patients with a bulging membrane were analyzed. In 21 patients with the dome type, gestational age at delivery (the UTI group versus the non-UTI group; 30.4 +/- 5.0 versus 26.4 +/- 1.9 weeks, p < 0.05), birth weight (1,436.8 +/- 708.3 versus 882.8 +/- 261.6 g, p < 0.05) and neonatal mortality rate (0/13 versus 3/8, p < 0.05) were all significantly improved by the use of UTI. On the other hand, in 22 patients with the hourglass type, there was no significant difference between the UTI group and the non-UTI group. The overall prevalence of histological chorioamnionitis was 60%.
CONCLUSION: These results suggest that UTI therapy is very effective in patients at risk for premature labor with a moderately developed bulging membrane during the second trimester. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11844908     DOI: 10.1159/000048011

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  1 in total

1.  Sensitive noninvasive marker for the diagnosis of probable bacterial or viral infection.

Authors:  Saeed A Jortani; Michael J Pugia; Ronald J Elin; Meera Thomas; Edward P Womack; Todd Cast; Roland Valdes
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.